Fei Ren Yao Wang Yongsheng Gao Xiangjiao Meng
10.3389/fonc.2022.971192
Front Oncol
2022 Aug 30;12:971192.
egfr mutation nsclc case report osimertinib pseudoprogression
CC BY
https://pubmed.ncbi.nlm.nih.gov/36110968/
Case Reports
PMC9468776
36110968
Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
2022